Safety and Efficacy of Preoperative SBRT and Radical Surgery for Soft Tissue Sarcoma of Extremities

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University

About this trial

Currently, the effectiveness and safety of preoperative hypo-fractionated radiotherapy in treating extremity soft tissue sarcomas remain inconclusive, warranting further investigation. Optimizing the neoadjuvant radiotherapy approach, including fractionation schedules and the interval between radiotherapy and surgery, is crucial to enhancing clinical efficacy while ensuring safety. This study proposes a multicenter, prospective, single-arm clinical trial utilizing preoperative SBRT for patients with high-grade extremity STS, tumors larger than 5 cm, or cases where achieving safe surgical margins is challenging due to involvement of surrounding blood vessels or nerves. The trial aims to preliminarily assess the impact of preoperative SBRT followed by radical surgery on surgical safety, quality of life, and tumor control in these patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Aged ≥18 years;

Confirmed diagnosis of soft tissue sarcomas;

Highly malignant soft tissue sarcomas;

Not received surgery, chemotherapy or other antitumor therapy;

Disqualifiers

Patients with soft tissue sarcoma of extremities with shallow tumor location, small size, low grade pathology and operable surgical resection;

Distant metastasis;

Received surgery or chemotherapy or other antitumor therapy;

Previously participated in other clinical trials;

Trial design

Design model

Single group

Treatments tested in this trial

  • stereotactic body raiotherapy

    Radiation

    Neoadjuvant stereotactic body radiation therapy followed by radical surgery for soft tissue sarcoma.

Treatment groups

20 Participants
are divided into 1 treatment group
Group A: radiotherapyExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Safety and tolerability of radiotherapy followed by radical surgery

Incidence of Treatment-Emergent Adverse events (CTCAE v5.0)

Time frame
120 days after radical surgery

Secondary outcomes

1

Extremity function and Quality of life by EORTC QLQ-C30

1 year after radical surgery

Time frame
Assessed up to 12 months
2

Recurrence free survival

From date of enrollment to the date of first documented recurrence

Time frame
1-,2-,3-year after radical surgery
3

Progression free survival

from date of enrollment to the date of first documented progression

Time frame
1-,2-,3-year after radical surgery
4

Overall survival

from date of enrollment to the date of death from any cause

Time frame
1-,2-,3-year after radical surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Second Affiliated Hospital, School of Medicine, Zhejiang University

Lead sponsor

The First Affiliated Hospital of Bengbu Medical University

Collaborator